Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 10/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | OSBP | P22059 | 1/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.53 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
| ▸ | POLA1 | P09884 | 1/20 | 0.52 |
| ▸ | TOP2A | P11388 | 1/20 | 0.52 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL29153013 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL3421500 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL14490136 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL17049790 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL25277367 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL15935528 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL23647982 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL18504407 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL14360501 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL21000300 | 1.00 | NPC1L1 (1.00) | NPC1L1USP2LMNAMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368024-B1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | AKOS BIOSCIENCES INC (US) | 2023-09-20 | — | — | EP | claimed |
| US-20220054429-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | AKOS BIOSCIENCES, INC. | 2022-02-24 | — | — | US | claimed |
| US-10514383-B2 | Diagnosis and treatment of neonatal encephalopathy | INFANDX AG (DE) | 2019-12-24 | — | — | US | claimed |
| US-20140308687-A1 | Method and Use of Metabolites for the Diagnosis and Differentiation of Neonatal Encephalopathy | INFANDX AG (DE) | 2014-10-16 | — | — | US | claimed |
| EP-2771696-A2 | METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY | InfanDx AG (DE) | 2014-09-03 | — | — | EP | claimed |
| WO-2013060788-A2 | METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY | INFANDX AG (DE) | 2013-05-02 | — | — | WO | claimed |
| US-20120202240-A1 | Method for Predicting the likelihood of an Onset of an Inflammation Associated Organ Failure | BIOCRATES LIFE SCIENCES AG | 2012-08-09 | — | — | US | claimed |
| EP-2460014-A1 | METHOD FOR PREDICTING THE LIKELIHOOD OF AN ONSET OF AN INFLAMMATION ASSOCIATED ORGAN FAILURE | BIOCRATES Life Sciences AG (AT) | 2012-06-06 | — | — | EP | claimed |
| EP-2284540-A1 | Method of diagnosing organ failure | BIOCRATES Life Sciences AG (AT) | 2011-02-16 | — | — | EP | claimed |
| WO-2011012553-A1 | METHOD FOR PREDICTING THE LIKELIHOOD OF AN ONSET OF AN INFLAMMATION ASSOCIATED ORGAN FAILURE | BIOCRATES LIFE SCIENCES AG (AT) | 2011-02-03 | — | — | WO | claimed |
| US-20100105574-A1 | CANCER STEM CELLS AND USES THEREOF | HOSPITAL FOR SICK CHILDREN (CA) | 2010-04-29 | — | — | US | claimed |
| US-20090036387-A1 | NOVEL CHEMICAL ENTITIES AFFECTING NEUROBLASTOMA TUMOR-INITIATING CELLS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-02-05 | — | — | US | claimed |
| US-20080038770-A1 | Cancer Stem Cells And Uses Thereof | HOSPITAL FOR SICK CHILDREN (CA) | 2008-02-14 | — | — | US | claimed |
| WO-2007079293-A2 | CANCER STEM CELLS AND USES THEREOF | HOSPITAL FOR SICK CHILDREN (CA) | 2007-07-12 | — | — | WO | claimed |
| US-20070123448-A1 | Novel chemical entities affecting neuroblastoma tumor-initiating cells | THE HOSPITAL FOR SICK CHILDREN (CA) | 2007-05-31 | — | — | US | claimed |
| US-20050101573-A1 | Meiosis regulating compounds | NOVO NORDISK A/S (DK) | 2005-05-12 | — | — | US | claimed |
| US-20020183283-A1 | Meiosis regulating compounds | FAARUP PETER (DK) | 2002-12-05 | — | — | US | claimed |
| US-20010003782-A1 | Meiosis regulating compounds | NOVA NORDISK A/S (DK) | 2001-06-14 | — | — | US | claimed |
| EP-1077992-A1 | MEIOSIS REGULATING COMPOUNDS | NOVO NORDISK A/S (DK) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058549-A1 | MEIOSIS REGULATING COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183283-A1 | Meiosis regulating compounds | SREBF2, SREBF1, TRIP13 | NPC1L1 360/4885USP2 1879/4885LMNA 1617/4885 |
| US-20010003782-A1 | Meiosis regulating compounds | SREBF2, SREBF1, TRIP13 | NPC1L1 360/4885USP2 1879/4885LMNA 1617/4885 |
| US-20050101573-A1 | Meiosis regulating compounds | SREBF2, SREBF1, TRIP13 | NPC1L1 360/4885USP2 1879/4885LMNA 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.